Professional Documents
Culture Documents
• Research Objectives
• Contribution
• Scope of the study
• Literature Review
• Research Methodology
• Research Findings
• Conclusions
• Further Research
%
Amit Rangnekar NMIMS-PhD-
2004
Strategic Shifts- Global Pharma Market
1995 2004
• Fragmentation • Consolidation
• Organic growth • Inorganic growth
• Ownership • Partnership/Outsourci
ng
• Domestic dominance
• Global reach
• Healthcare/Chemicals
focus • Pharma focus
• Big Pharma emergence • Big Pharma
dominance
GPM
Global
Industry
Consolidation GPM Consolidation
Stayers
Fringers Survivors Strategic
Responsiveness
Followers
Firms
Firms Firms
Firms in
in The
The Top
Top 100
100 Firms
Firms
common
common to to Big
Big Pharma
Pharma pharma
pharma firms
firms outside
outside
Big Pharma for
Big Pharma for atleast
atleast 11 of
of 2004,
2004, the
the
1995
1995 && year
year between
between besides
besides the
the Top
Top 100
100
2004
2004 1995
1995 & & 2004
2004 survivors
survivors pharma
pharma
and
and still
still &
& the
the firms
firms
existing
existing stayers
stayers of
of 2004
2004
Amit Rangnekar NMIMS-PhD-
2004
Strategic Management Frameworks
Ansoff’s SR Framework
Data Analysis
Hypothesis Testing
Ranbaxy Pfize
Organi
Roche GSK r
A+
DrReddys
c
NovoNordisk
SA+
Merck(US)
o
ViPharmAurobindo r
Merck(Ger) Wyeth
Taro AkzoNobel
Organi
c
BlueCross
<$1Amit
Bn Rangnekar
<$5 Bn
NMIMS-PhD- <$20 >$20
Bn Bn
Map not to scale, indicative 2004 Scale SA= Strategic Alliances & Acquisitions
Strategy Mix
M&A
Organic Strategic
Growth Alliances
Strategic
Divestmen Acquisition
ts s
Amit Rangnekar NMIMS-PhD-
2004
Intra-Survivors Strategy Mix
Survivors Pfizer GSK Merck Roche Novartis BMS
Biotech
• Cover diverse segments- psoriasis, vaccines,
cancer, metabolism and virology
• Command a price premium, generics deterrent
due to their manufacturing complexities
• Not shown as a separate category, because intra-
category comparison with non-biological
molecules becomes difficult
Personalised medicine
• Little evidence in 2004
• Issues of feasibility, safety, ethics & price
Amit Rangnekar NMIMS-PhD-
2004
PBM, HMO, Medical Insurance